Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pavlo Gilchuk

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
Cell|May 18, 2019
A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer InterfaceSandhya Bangaru, Shanshan Lang, Michael Schotsaert, et al.
Cell Reports. Medicine|December 1, 2023
A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protectionLucas J Adams, Laura A VanBlargan, Zhuoming Liu, et al.
Cell Reports|April 14, 2021
Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodiesCharles D Murin, Pavlo Gilchuk, Philipp A Ilinykh, et al.
Cell Host & Microbe|November 24, 2019
Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in MiceIuliia M Gilchuk, Sandhya Bangaru, Pavlo Gilchuk, et al.
Nature Communications|July 12, 2018
A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HASandhya Bangaru, Heng Zhang, Iuliia M Gilchuk, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2021
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike proteinNaveenchandra Suryadevara, Swathi Shrihari, Pavlo Gilchuk, et al.
Frontiers in Immunology|August 2, 2021
Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human PlasmaPavlo Gilchuk, Adrian Guthals, Stefano R Bonissone, et al.
Cell Host & Microbe|April 23, 2020
Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other AntibodiesPhilipp A Ilinykh, Kai Huang, Rodrigo I Santos, et al.
Plos Pathogens|May 18, 2022
Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER regionClara T Schoeder, Pavlo Gilchuk, Amandeep K Sangha, et al.
The Journal of Clinical Investigation|December 1, 2025
A protective and heterosubtypic antibody lineage targeting the influenza A virus neuraminidase active siteTy A Sornberger, Rachael M Wolters, Iuliia M Gilchuk, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
Cell|May 18, 2019
A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer InterfaceSandhya Bangaru, Shanshan Lang, Michael Schotsaert, et al.
Cell Reports. Medicine|December 1, 2023
A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protectionLucas J Adams, Laura A VanBlargan, Zhuoming Liu, et al.
Cell Reports|April 14, 2021
Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodiesCharles D Murin, Pavlo Gilchuk, Philipp A Ilinykh, et al.
Cell Host & Microbe|November 24, 2019
Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in MiceIuliia M Gilchuk, Sandhya Bangaru, Pavlo Gilchuk, et al.
Nature Communications|July 12, 2018
A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HASandhya Bangaru, Heng Zhang, Iuliia M Gilchuk, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2021
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike proteinNaveenchandra Suryadevara, Swathi Shrihari, Pavlo Gilchuk, et al.
Frontiers in Immunology|August 2, 2021
Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human PlasmaPavlo Gilchuk, Adrian Guthals, Stefano R Bonissone, et al.
Cell Host & Microbe|April 23, 2020
Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other AntibodiesPhilipp A Ilinykh, Kai Huang, Rodrigo I Santos, et al.
Plos Pathogens|May 18, 2022
Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER regionClara T Schoeder, Pavlo Gilchuk, Amandeep K Sangha, et al.
The Journal of Clinical Investigation|December 1, 2025
A protective and heterosubtypic antibody lineage targeting the influenza A virus neuraminidase active siteTy A Sornberger, Rachael M Wolters, Iuliia M Gilchuk, et al.
Pageof 8